Shopping Cart
Remove All
Your shopping cart is currently empty
ALX-0651 is a dual-complementarity-determining region humanized monoclonal antibody inhibitor targeting CXCR4. It can inhibit the transport of hematopoietic stem cells as well as the progression and metastasis of tumors. ALX-0651 is applicable for research in treating non-Hodgkin's lymphoma and multiple myeloma.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
| Description | ALX-0651 is a dual-complementarity-determining region humanized monoclonal antibody inhibitor targeting CXCR4. It can inhibit the transport of hematopoietic stem cells as well as the progression and metastasis of tumors. ALX-0651 is applicable for research in treating non-Hodgkin's lymphoma and multiple myeloma. |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.